HRT and BRCA Mutation: 9 Facts That Change the Answer

The HRT Index Editorial TeamIndependent women's health research

Last reviewed: August 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 6, 2026 · Last verified: August 6, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Match the care route to your cancer-risk history

Find My HRT Path helps organize symptoms, surgery history, uterus status, safety history, budget, and state. It does not interpret a genetic result, replace genetics or oncology care, or clear systemic HRT after breast cancer.

Find My HRT Path

For a woman with a confirmed BRCA1 or BRCA2 pathogenic variant, no personal history of breast cancer, and both ovaries removed before natural menopause, HRT is generally offered until about age 51. HRT and BRCA mutation becomes a different decision after breast cancer, with ovaries still in place, or when combined estrogen-progestogen therapy continues for years.^[1]^[2]

Your situation	Where the evidence points	How directly does the evidence apply?
Confirmed BRCA1/2 pathogenic variant, no breast cancer, both ovaries removed before natural menopause	HRT should be offered unless another contraindication applies, then reassessed around age 51	Directly studied and guideline-addressed
Same, with no uterus	Estrogen-only therapy is possible; this is where the most favorable observational findings sit	Directly studied, but not randomized
Same, with a uterus	Systemic estrogen generally needs a progestogen for endometrial protection; overall combined-therapy estimates are not clearly elevated, but long-duration data are less settled	Directly studied, with thinner subgroup evidence
Under 45 at ovary removal and using combined therapy for at least 5 years	One 2026 analysis found an elevated but imprecise subgroup estimate: adjusted HR 2.31 (0.99–5.40; P=.05)^[2]	A real signal, not a settled conclusion
Past the natural menopause age	Routine continuation is not specifically supported for BRCA carriers because the direct evidence runs out^[1]	Not directly established
Preventive bilateral mastectomy completed	The 2024 guideline allows decisions beyond natural menopause to follow ordinary population-risk principles more closely^[1]	Guideline-supported, limited direct HRT data
Breast cancer, DCIS, tamoxifen, or aromatase inhibitor use	Systemic HRT is usually contraindicated or oncology-led; local vaginal treatment is a separate question	Different clinical category
Ovaries still in place	Post-oophorectomy findings do not directly answer your question; one newer postmenopausal BRCA study included natural and surgical menopause^[3]	Partly studied, not the same scenario

Read that last column carefully. “The evidence is reassuring” is only honest when the women in the study actually resemble the woman reading the sentence.

Here’s the part almost nobody tells her: there is risk on the other side of this decision too. Skipping hormones after early ovary removal is not the automatically safe default it gets treated as. We’ll get to what not taking HRT can cost — because that section changes how most women read everything else.

Written for readers in the United States. FDA labels, controlled-substance rules, provider access, and insurance details are U.S.-specific. The most detailed BRCA-specific menopause guideline we found is a 2024 joint British guideline, so it is clearly labeled when used.

Best for you if:

You have a confirmed pathogenic or likely pathogenic BRCA1 or BRCA2 variant.
You are weighing, scheduled for, or recovering from removal of both ovaries.
You have never had breast cancer or DCIS.
Someone told you “no hormones with your gene” and never explained which evidence they meant.

Not for you if:

You have had breast cancer or DCIS. Different question, different answer. Go to What if you have already had breast cancer?, then take it to your oncology team.
You take tamoxifen or an aromatase inhibitor. That is an oncology-led medication decision.
Your report says variant of uncertain significance, or VUS. A VUS is not a confirmed BRCA pathogenic variant. Go to What if my result was a VUS?.
You are deciding whether to have risk-reducing surgery. That decision is driven by ovarian-cancer prevention, gene, age, fertility plans, and your surgical team. Bring the menopause plan into that conversation; do not let fear of menopause make the cancer-prevention decision for you.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Is online HRT care the right starting point for a BRCA carrier? {#before-you-go-further}

For many BRCA carriers, a general telehealth intake should not be the first or only clinical stop. A menopause-trained virtual clinician can sometimes help with symptoms and treatment, but the prescribing plan may need to connect with genetics, breast screening, surgery, gynecology, or oncology before a prescription is the right next move.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Does that sound like where you are? Get a private best-fit care route and two backup options, with FDA-approved and compounded options labeled separately. Find my HRT path → Free. About 90 seconds. No email. Your health answers stay in your browser.

What did The HRT Index actually verify? {#verification}

This is editorial research, not a clinical review. We read the full studies and current source documents behind the page, checked the live provider pages used in the care-route section, and recorded what each source can and cannot prove. The date below applies to this verification pass, not to facts that were merely repeated from older summaries.

Verified August 6, 2026:

Two current FDA labels: Divigel, Reference ID 5744952, revised February 2026; and Bijuva, Reference ID 5744948, revised February 2026. We checked Section 4, Contraindications, line by line.^[4]^[5]
The FDA’s February 12, 2026 labeling action and its current six-product list.^[6]^[7]
The August 2024 BGCS/BMS joint guideline, including its BRCA-specific recommendations, grades, specialist-referral criteria, vaginal-estrogen section, route guidance, and bone-monitoring recommendations.^[1]
The April 2026 JAMA Network Open cohort of 919 cancer-free carriers after risk-reducing bilateral oophorectomy.^[2]
The JNCI analysis published online December 17, 2025, including the crucial fact that it was a broader postmenopausal cohort rather than a pure post-oophorectomy cohort.^[3]
The older post-oophorectomy studies and meta-analysis used in the evidence ledger below.^[8]^[9]^[10]^[11]^[12]^[13]
Current provider-stated care, access, pricing, and cancellation details for Midi Health and current marketplace terms for Sesame. Commercial claims are labeled as provider-stated rather than converted into medical endorsements.^[14]^[15]^[16]^[17]

What we did not do: examine anyone, review a medical record, verify an individual clinician’s competence, or clear HRT for a reader. This page can show where the evidence points. Your clinician has to decide whether it applies to you.

Which nine facts change the answer for HRT and BRCA mutation? {#nine-factors}

There is no single HRT answer for every BRCA carrier. Nine facts move the decision, and one of them — a personal history of breast cancer — can outweigh all the others combined. Identifying your nine answers is the fastest way to replace a reflexive yes-or-no with a useful clinical conversation.

Does your report say pathogenic, likely pathogenic, or VUS? A VUS is not a confirmed pathogenic variant.
Have you ever had breast cancer or DCIS? This is the biggest fork.
Are you taking tamoxifen or an aromatase inhibitor? That moves the decision under oncology.
Were both ovaries removed, and at what age?
Do you still have a uterus or any endometrial tissue that needs protection?
Are your symptoms systemic — hot flashes, night sweats, sleep disruption — or local — dryness, burning, painful sex, urinary symptoms?
Would the regimen be estrogen alone or estrogen plus a progestogen?
How long have you used it, and how old are you now?
Have you had a preventive bilateral mastectomy?

Do not add these up like a score. A prior hormone-receptor-positive breast cancer can settle the systemic-HRT question on its own. But if you can answer all nine, you can walk into the appointment asking for a decision instead of accepting a reflex.

Why do carriers and breast-cancer survivors get different answers? {#previvor-vs-survivor}

Most confusing BRCA-and-HRT advice starts by collapsing two groups into one: a cancer-free carrier and a woman previously treated for breast cancer. They do not have the same evidence base or the same drug-label problem. The two FDA labels we checked contraindicate current or prior breast cancer; they do not list BRCA status or family history.

There is a word many cancer-free carriers use for themselves: previvor — someone living with a cancer predisposition who has not had that cancer. This page’s reassuring center is about previvors, particularly after risk-reducing removal of both ovaries.

We opened the current Divigel and Bijuva labels ourselves. In Section 4, the contraindications include:

abnormal genital bleeding of unknown cause;
current breast cancer or a history of breast cancer;
estrogen-dependent neoplasia;
active or prior venous thromboembolism;
active or prior arterial thromboembolic disease;
serious hypersensitivity to the product;
liver impairment or disease; and
known thrombophilic disorders.^[4]^[5]

Now here is what is not in either Section 4 list: BRCA1, BRCA2, pathogenic variant, genetic predisposition, or family history of breast cancer.

Read that again. The two current labels we checked contraindicate the product for a woman with breast cancer or a history of breast cancer. They do not create a separate contraindication for a cancer-free woman because she carries BRCA1 or BRCA2.

That is not proof that HRT is right for every carrier. It is proof that “BRCA is on the FDA contraindication list” is not an accurate explanation for refusing it.

If you have had breast cancer or DCIS, skip to that section. We wrote it for you, and it does not pretend the previvor answer is yours.

Does HRT cancel the breast-cancer risk reduction from ovary removal? {#does-hrt-cancel-surgery}

The best available evidence says short-term HRT does not appear to cancel the breast-cancer risk reduction from risk-reducing ovary removal in cancer-free BRCA carriers. That conclusion comes from observational cohorts and a meta-analysis, not a randomized trial. Estrogen-only findings are consistently more favorable than combined-therapy findings.

This is the question. Everything else on this page is downstream of it.

You had — or are considering — surgery to cut cancer risk. The fear is simple and reasonable: if I take estrogen afterward, am I handing back what I just paid for?

The evidence ledger

Study	Population and design	What it found	What it cannot prove
Rebbeck et al., J Clin Oncol 2005	BRCA1/2 carriers; prospective cohort after bilateral prophylactic oophorectomy	Short-term HRT did not negate the surgery’s observed breast-cancer risk reduction	Long-term effects or product-specific safety
Eisen et al., JNCI 2008	472 postmenopausal BRCA1 carriers; matched case-control; natural and surgical menopause	Estrogen-only OR 0.51 (0.27–0.98); combined OR 0.66 (0.34–1.27), not significant	A causal protective effect
Kotsopoulos et al., JAMA Oncology 2018	872 BRCA1 carriers after oophorectomy; prospective cohort	Any HRT HR 0.97 (0.62–1.52); 10-year cumulative incidence 12% with estrogen alone vs 22% with estrogen plus progesterone	That progestogen caused the difference
Marchetti et al. meta-analysis, 2018	3 post-RRSO studies; 1,100 carriers	Overall HR 0.98 (0.63–1.52); no significant increase	Precision for BRCA2, long duration, or specific regimens
Michaelson-Cohen et al., Eur J Cancer 2021	306 BRCA1/2 carriers after RRSO; retrospective	No increase at age 45 or younger; approximately threefold association among carriers older than 45	Whether age, selection, regimen, or another factor drove the signal
Kim et al., nationwide Korean study, 2024	151 BRCA carriers after RRSO; retrospective	No significant relationship between short-term HRT and breast cancer; confidence interval was wide	A small or long-term effect
Kotsopoulos et al., JNCI 2026	676 matched pairs after menopause; not a pure post-oophorectomy cohort	Estrogen-only HR 0.37 (0.24–0.57); combined HR 0.94 (0.54–1.63)	A post-RRSO-only conclusion or protection caused by estrogen
Regev-Sadeh et al., JAMA Network Open 2026	919 cancer-free BRCA1/2 carriers after risk-reducing bilateral oophorectomy	Per-year estrogen-only HR 0.90 (0.81–0.99); any combined therapy HR 1.06 (0.67–1.68)	A randomized causal result or complete long-term reassurance
Same JAMA study: longest combined exposure	Women younger than 45 at surgery using combined therapy for at least 5 years	Adjusted HR 2.31 (0.99–5.40; P=.05)	A settled harm signal; the estimate was imprecise and subgroup-sized

The pattern is not a vote count. The evidence does not say every regimen is equally reassuring. It says the overall post-surgery record has not shown a substantial breast-cancer increase, while estrogen-only data repeatedly look more favorable and long-duration combined therapy remains the weak spot.

The outlier that did not disappear

The 2021 Michaelson-Cohen study found a result the other post-surgery cohorts did not: HRT after RRSO was associated with about three times the breast-cancer risk among carriers older than 45, while no increase appeared at 45 or younger.^[12]

Here is something we verified that changes how that result should be read. Rachel Michaelson-Cohen is also a named coauthor on the larger April 2026 JAMA cohort. That later study had a mean surgery age of 47.6 and did not reproduce an overall increase.^[2]

That does not erase the 2021 result. It tells you the evidence moved. A named investigator from the earlier signal went on to help produce a larger study in a similar age range that reached a different overall result.

What the record is — and what it is not

No randomized trial has assigned BRCA carriers to HRT or no HRT. Every risk estimate here is observational.
Observational studies can be confounded. HRT users may differ from nonusers in screening, surgery timing, health, clinician access, and other unmeasured ways.
Lower observed risk is not cancer prevention. The estrogen-only findings do not prove estrogen protects a BRCA carrier.
Combined therapy deserves its own sentence. The overall estimate was not elevated, but the five-year-plus subgroup after surgery before 45 was concerning enough to show rather than bury.
The population boundary matters. These reassuring post-surgery studies excluded women with prior breast cancer.
The JAMA variant mix matters too. More than 90% carried one of three Ashkenazi Jewish founder variants, so precision for rarer BRCA variants is not separately established.^[2]

The Women’s Health Initiative headlines most women remember came from an older population with intact ovaries and an average age around 63. That evidence matters, but it is not a substitute for evidence in a 38-year-old who entered abrupt surgical menopause after risk-reducing surgery.

You are not that woman.

Not sure whether online care even belongs in your next step? Use Find My HRT Path to separate specialist-first histories from situations that may fit virtual menopause care. Show me my safest starting route →

What did the two newest BRCA studies actually find? {#newest-studies}

Two major analyses published from December 2025 through April 2026 strengthened the overall reassuring picture, but they did not study the same population. JAMA studied only cancer-free women after risk-reducing bilateral oophorectomy. JNCI studied postmenopausal carriers more broadly, so it is supporting evidence rather than a pure post-surgery replication.

	JNCI, published online December 2025	JAMA Network Open, April 2026
Design	Prospective 1:1 matched analysis after menopause	Retrospective cohort after risk-reducing bilateral oophorectomy
Size	676 HRT users matched to 676 nonusers	919 carriers: 496 BRCA1, 423 BRCA2
Cancer history	Excluded	Excluded
Prior preventive bilateral mastectomy	Excluded	Excluded
Menopause route	Natural or surgical; not a pure post-oophorectomy cohort	All had risk-reducing bilateral oophorectomy
Mean follow-up	5.6 years	8.8 years
Variant mix	International hereditary-cancer cohort	828 of 919 (90.1%) carried one of three Ashkenazi Jewish founder variants
Breast cancers	87/676 users (12.9%) vs 128/676 nonusers (18.9%)	144 total (16%)
Estrogen only	HR 0.37 (0.24–0.57)	Per-year HR 0.90 (0.81–0.99)
Estrogen plus progestogen	HR 0.94 (0.54–1.63)	Any use HR 1.06 (0.67–1.68)
BRCA1 vs BRCA2	Broad patterns were similar	Estrogen-only per-year result was significant in BRCA1, not BRCA2
Hard boundary	Cannot be described as entirely “HRT after ovary removal”	Does not answer HRT after prior breast cancer

Most pages stop at “two new studies were reassuring.” That sentence is too blunt to be useful.

The JNCI analysis adds large, modern evidence about HRT after menopause in cancer-free BRCA carriers. It does not let us pretend all 1,352 women had undergone oophorectomy.

The JAMA cohort is the cleaner answer to the post-surgery question. Its overall results were reassuring, but its combined-therapy subgroup is exactly why the final answer is not “all HRT is the same.”

And the boundary that matters most remains unchanged: both analyses excluded women with a cancer history. When someone uses these studies to reassure a breast-cancer survivor about systemic HRT, they are crossing a line the studies did not cross.

What do BRCA-specific menopause guidelines say? {#guidelines}

The most detailed guideline we found says HRT should be offered after premenopausal oophorectomy until the usual age of natural menopause unless the woman has a personal history of breast cancer. It also says high-risk gene carriers should have access to specialist menopause care and that routine continuation beyond natural menopause lacks a BRCA-specific evidence base.

The August 2024 British Gynaecological Cancer Society and British Menopause Society joint guideline is not a U.S. drug label and does not replace U.S. oncology guidance. It is still unusually useful because it addresses the exact gene-carrier scenario and grades its recommendations.^[1]

Question	BGCS/BMS position	Grade
After premenopausal oophorectomy, no breast-cancer history	HRT should be offered until the usual age of natural menopause	C
Continue beyond natural menopause	BRCA-specific evidence is lacking; not routinely recommended	D
Continue after preventive bilateral mastectomy	May be considered using principles for women at ordinary population risk	D
Remove the uterus during RRSO just because of BRCA1/2	Hysterectomy is not routinely indicated without another endometrial-risk gene or separate clinical reason	D
Who should have specialist access	Women with high-risk cancer gene variants are a named referral group	Practice standard
Bone monitoring	Baseline DEXA or FRAX/DEXA should be considered after premenopausal treatment-induced menopause	B
Route	Transdermal estradiol is favored when thrombotic or stroke risk is relevant	A
Compounded bioidentical HRT	Not recommended	D

Now look at what that table is actually saying.

The center is clearer than the edges. The clearest situation is a cancer-free carrier who loses both ovaries before natural menopause. The unsettled parts are duration past natural menopause, BRCA2-specific precision, and prolonged combined therapy.

If you were told only “it’s complicated,” ask which edge applies to you. Complexity is real. It should not be used as camouflage for never opening the guideline.

Does the answer change for BRCA1 versus BRCA2? {#brca1-vs-brca2}

The recommendation after premenopausal risk-reducing ovary removal is broadly similar for BRCA1 and BRCA2, but the evidence is not equally deep. BRCA1 dominates many older HRT studies. BRCA2-associated tumors are more often hormone-receptor-positive, while BRCA1-associated tumors are more often triple-negative, which can make BRCA2 counseling feel more cautious.

Decision fact	BRCA1	BRCA2
Typical risk-reducing surgery timing	Usually earlier	Usually later
Tumor pattern at a population level	More often triple-negative	More often hormone-receptor-positive
Depth of HRT evidence	More direct BRCA1-only data	Fewer precise gene-specific estimates
JAMA 2026 estrogen-only result per year	HR 0.87 (0.77–0.98)	HR 0.96 (0.82–1.12), not significant
JNCI 2026	No substantial overall increase	Broad pattern similar, but subgroup precision remains limited
Bottom line after early oophorectomy, no cancer	HRT can be offered	HRT can be offered, with less gene-specific certainty

BRCA2 caution has at least two legitimate roots:

The tumor biology differs. NCI’s BRCA review says BRCA1-associated breast cancers are more likely to be triple-negative, while most BRCA2-associated breast cancers are hormone-receptor-positive.^[18]
The dataset is thinner. Several influential studies enrolled only BRCA1 carriers or were too small to estimate BRCA2 separately.

What we removed from the draft is the claim that BRCA1 carriers are more likely to lose their uterus while BRCA2 carriers keep it. We found no primary evidence strong enough to make that anatomy claim. Uterus status matters enormously, but it should be asked — not guessed from the gene.

Do you need progesterone if you kept your uterus? {#regimen-fork}

If a uterus or endometrial tissue remains, systemic estrogen generally requires a progestogen or another accepted method of endometrial protection. This matters because the most favorable BRCA observations are concentrated in estrogen-only users. Combined therapy is not proven harmful overall, but the long-duration subgroup signal means it cannot be described as equally settled.

This is the single most useful chain on the page.

Step one. BRCA1 or BRCA2 alone is not a routine reason to remove the uterus during risk-reducing ovary surgery. The BGCS/BMS guideline says hysterectomy is not indicated unless another genetic or clinical reason exists.^[1]

Step two. If the uterus remains, systemic estrogen without endometrial protection raises the risk of endometrial hyperplasia and cancer. That is why a progestogen is generally added.^[4]^[5]

Step three. The breast-cancer evidence is more favorable for estrogen alone than for estrogen plus a progestogen.

Your anatomy and regimen	What the evidence can honestly say
No uterus; estrogen alone	Most favorable observational findings; no proof of cancer protection
Uterus present; estrogen plus progestogen	Overall estimates have not shown a substantial increase, but confidence intervals are wide and the longest-exposure subgroup is unresolved
Uterus present; combined therapy for at least 5 years after surgery before 45	JAMA adjusted HR 2.31 (0.99–5.40; P=.05); real enough to discuss, too imprecise to declare settled harm
Preventive bilateral mastectomy completed	Guideline allows the broader decision to move closer to population-risk principles; endometrial protection is still needed if the uterus remains

The body you wake up with after surgery decides which regimens are medically available. It should not decide whether anyone explains the tradeoff to you.

Two questions to raise with your prescriber — not products to demand:

Which progestogen and schedule are you recommending, and why? General-population research suggests breast-risk profiles may differ between micronized progesterone and some synthetic progestins, but that evidence is not BRCA-specific.
What is the review plan before five years? The combined-therapy signal is a reason to revisit duration, route, dose, symptoms, and mastectomy status instead of putting the prescription on autopilot.

And one thing to be firm about: nobody should remove a healthy uterus solely to qualify for estrogen-only therapy. The evidence and guideline do not support that shortcut.

What if your ovaries are still in place? {#ovaries-intact}

The reassuring post-oophorectomy evidence does not directly answer HRT use in a BRCA carrier whose ovaries remain. The 2026 JNCI analysis offers broader postmenopausal evidence, but it mixed natural and surgical menopause. Your age, natural menopause status, uterus, symptoms, and breast-risk plan need their own assessment.

This distinction matters because “BRCA carrier using HRT” can describe two biologically different situations:

a 38-year-old whose ovaries were removed and is replacing hormones lost years before natural menopause; or
a 53-year-old whose ovaries remain and is considering HRT after natural menopause.

The first woman dominates the BRCA-specific guideline discussion. The second is closer to an ordinary menopause decision layered on top of elevated genetic breast risk.

The JNCI matched analysis is useful here because it was not limited to women after surgery. But it still excluded prior cancer and preventive bilateral mastectomy, and it remains observational.

Practical next question: ask your clinician which evidence set they are applying — post-RRSO replacement, general menopause HRT, or breast-cancer survivorship. Those are not interchangeable.

What is the risk of not taking HRT after early ovary removal? {#risk-of-not-taking-it}

No treatment is not automatically the low-risk option after early bilateral oophorectomy. Surgical menopause can affect bone, cardiovascular health, vasomotor symptoms, sleep, sexual function, and quality of life. Observational mortality findings are not uniform and do not prove HRT prevents death, but they are strong enough to reject “do nothing is always safer.”

Here is the open loop from the top of the page.

You have spent this whole search worrying about what HRT might do to you. Almost nobody has told you what abrupt estrogen loss might do.

Bone: the prospective WHAM study documented substantial loss of bone density and bone strength after premenopausal risk-reducing bilateral salpingo-oophorectomy.^[19]
Monitoring: the BGCS/BMS guideline says baseline DEXA or FRAX with DEXA should be considered after premenopausal treatment-induced menopause.^[1]
Long-term health: observational cohorts have linked early bilateral oophorectomy, particularly without estrogen use, to higher cardiovascular and mortality risk in some populations. Other large cohorts have produced less consistent mortality findings. That is association, not proof that HRT prevents death.^[20]^[21]^[22]
Symptoms and function: abrupt surgical menopause can produce immediate hot flashes, sleep disruption, vaginal and urinary symptoms, sexual pain, mood changes, and loss of quality of life.

We are going to be careful with this. We are not saying HRT prevents death. We are saying that treating “no hormones” as automatically cautious is not supported by the full evidence.

The care gap nobody should have to discover by accident

Source	Population	What it reported
ASCO 2026 cross-sectional survey	259 eligible BRCA carriers after surgical menopause; prior breast cancer excluded	64.4% used systemic MHT; 20.85% said menopausal symptoms were not discussed before RRSO^[23]
FORCE member survey presented at ASCO 2017	Cancer-free BRCA carriers after surgery	13% used HRT^[24]
Same 2017 conference survey	BRCA carriers with prior cancer	28% used HRT^[24]
BGCS/BMS synthesis of published series	General post-surgery care	8%–47% used HRT^[1]
BGCS/BMS synthesis	Specialist high-risk centers	74% used HRT^[1]

Sit with those rows.

The 2017 and 2026 surveys are not a clean time trend: they used different samples and recruitment methods. The 2026 respondents were predominantly white, insured, college-educated, higher-income, and receiving urban or suburban care, so 64.4% is not a national population estimate. The surveys do prove that one headline percentage is not the story — and the newest one still found that about one in five eligible women said menopausal symptoms were never discussed before surgery.^[23]

The contrast between 8%–47% in general settings and 74% in specialist centers does not prove the specialist caused treatment. It does show that where a woman is seen is associated with whether the guideline becomes a real conversation.

The 2017 FORCE survey also recorded what women feared after menopause: weight gain 83%, low libido and sexuality 78%, heart disease 77%, and bone loss 65%.^[24]

You should not have to get lucky with who is in the room. Bring the nine-factor list and the guideline position to a clinician who routinely handles inherited cancer risk. Find the right starting route for my history →

What does the current FDA label actually say about BRCA? {#fda-label}

The current Divigel and Bijuva labels list current or prior breast cancer as a contraindication. Neither label lists BRCA1, BRCA2, genetic predisposition, pathogenic variant, or family history in Section 4. That does not clear HRT for every carrier; it does correct the claim that the gene itself appears on the contraindication list.

Our August 2026 label check

Product	FDA label checked	Revision	Breast-cancer contraindication	BRCA named in Section 4?
Divigel (estradiol gel)	Reference ID 5744952	February 2026	Current or history of breast cancer	No
Bijuva (estradiol/progesterone)	Reference ID 5744948	February 2026	Breast cancer or history of breast cancer	No

You can reproduce this check:

Open the current prescribing information at Drugs@FDA.
Find Section 4 — Contraindications.
Read the list rather than relying on an old patient handout.
Record the revision date and Reference ID.
Recheck the label for the exact product prescribed to you.

What changed in February 2026?

On February 12, 2026, FDA approved labeling changes for six menopause hormone products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. The revised boxed warning no longer carries the previous generalized wording about cardiovascular disease, breast cancer, and probable dementia for those six products.^[6]^[7]

What that does not mean:

It does not remove current or prior breast cancer from product contraindications.
It does not make HRT risk-free.
It was not a BRCA-specific action.
It does not automatically update every estrogen or estrogen-progestogen product.
It does not replace individual prescribing information.

What it does mean is simpler: a clinician or patient should not use a superseded boxed warning as if no label changed in 2026.

How long can a BRCA carrier stay on HRT, and what happens around 51? {#duration}

BRCA-specific guidance supports HRT through roughly the natural menopause age after premenopausal ovary removal, then calls for reassessment. Routine continuation beyond that age is not specifically supported because direct evidence is thin. A preventive bilateral mastectomy can change the framework, but age 51 is a review point — not a trapdoor.

Before roughly 51: the BGCS/BMS guideline says HRT should be offered after premenopausal oophorectomy unless there is a personal breast-cancer history.
Around 51: reassess symptoms, bone health, breast-risk strategy, uterus status, regimen, dose, route, and patient preference.
Beyond 51: routine BRCA-specific continuation is not recommended because the evidence base is limited.
After preventive bilateral mastectomy: continuation may be considered using ordinary population-risk principles.

The useful reframe — without pretending exposure is zero

The guideline explains that HRT in a younger woman replaces ovarian hormones her body would otherwise still be producing and says breast-risk exposure years can be considered from the age of natural menopause.^[1]

That is a powerful clinical reframe. It does not mean fourteen years of treatment before 51 creates literally zero biological exposure. It means the decision is being made in the context of premature hormone loss, not elective addition of hormones decades after natural menopause.

If surgery happened at 37, treatment to 51 is fourteen years of replacement during years when ovarian hormones would ordinarily still be present. That is why clinicians should not apply a hard “five years total” rule designed for a different population without explaining the mismatch.

What to ask at the review point:

What benefits am I still getting?
What symptoms return if I reduce or stop?
Has my DEXA result changed?
Has my breast-risk plan changed?
Does my uterus still require the same progestogen plan?
Have I crossed into a duration range where the combined-therapy evidence is thinner?
Who owns follow-up if my genetics, gynecology, and menopause care are split across teams?

Does a preventive bilateral mastectomy change the HRT answer? {#mastectomy}

Yes. The 2024 guideline says that a cancer-free carrier who has completed bilateral risk-reducing mastectomy can have HRT beyond natural menopause considered under the same broad principles used for women at ordinary population risk. That relaxes the BRCA-specific duration ceiling, but it does not make residual breast risk or other HRT risks disappear.^[1]

The logic is straightforward: preventive mastectomy removes most, but not all, breast tissue. That materially changes the breast-risk side of the equation.

Two honest limits:

Preventive mastectomy does not reduce breast-cancer risk to zero.
It does not erase clotting, stroke, liver, bleeding, endometrial, or product-specific considerations.

And it does not remove the need for a progestogen if a uterus remains and systemic estrogen is used.

If you have had preventive bilateral mastectomy and someone is enforcing a hard stop at 51 without acknowledging the guideline exception, that conversation deserves to be reopened.

Is vaginal estrogen a different decision? {#vaginal-estrogen}

Yes. Low-dose vaginal estrogen is local treatment for vaginal and urinary symptoms, not the same exposure as systemic HRT used for hot flashes and night sweats. The BRCA-specific guideline says vaginal estrogen is generally not contraindicated even when systemic HRT is unsuitable, with oncology involvement for breast-cancer survivors.

If your main problem is dryness, burning, painful sex, urinary urgency, or recurrent urinary symptoms — not body-wide hot flashes — this may be the section you needed.

The BGCS/BMS guideline makes a memorable comparison: with current low-dose vaginal products, the total amount administered over a full year is roughly comparable to one systemic oral dose.^[1] That does not mean the products create identical blood levels. It illustrates how small the annual administered amount can be.

The 2018 consensus from The Menopause Society and ISSWSH specifically addresses women at high breast-cancer risk, including BRCA carriers. It recommends nonhormonal options first in breast-cancer survivors, then individualized discussion of local hormone therapy when symptoms persist.^[25]

Symptom pattern	Treatment question
Hot flashes, night sweats, widespread sleep disruption	Systemic treatment question
Dryness, burning, painful sex, urinary symptoms	Local genitourinary treatment question
Both	May need separate systemic and local decisions
Prior breast cancer or active endocrine therapy	Oncology-informed local-treatment decision

Moisturizers and lubricants can help, but “just use lube” is not a complete answer when estrogen loss has changed the tissue itself.

Our complete guide is vaginal estrogen.

What if you have already had breast cancer or DCIS? {#prior-breast-cancer}

This is a genuinely different question. Systemic HRT is usually contraindicated after breast cancer and is not routinely recommended after hormone-receptor-positive disease. Exceptional use may be discussed for severe symptoms in carefully selected cases, particularly after triple-negative disease, but that is an oncology-led decision — not an online eligibility shortcut.

We are not going to pretend the reassuring middle of this page is yours. It is not. But we are also not going to leave you with “suffer.”

Where the guideline stands

The BGCS/BMS guideline says:

systemic HRT is usually contraindicated after breast cancer;
it should not be routinely recommended after estrogen- or progesterone-receptor-positive disease;
individual consideration may occur when symptoms are severe and nonhormonal options have failed;
short-term systemic HRT after triple-negative breast cancer may be considered case by case; and
local vaginal estrogen is a separate, more permissive decision after nonhormonal measures, with oncology involvement.^[1]

A 2026 narrative review proposed a structured approach for selected BRCA carriers with prior triple-negative breast cancer. It is a review framework, not a trial and not a new blanket guideline. Its practical value is in the questions it forces: receptor status, remission, residual breast tissue, symptom severity, bone health, nonhormonal failures, route, duration, and surveillance.^[26]

Nonhormonal options that are actually in the evidence base

For vasomotor symptoms, current evidence-supported options include:

certain SSRIs and SNRIs;
gabapentin;
oxybutynin;
fezolinetant; and
elinzanetant, FDA-approved in October 2025 as Lynkuet.^[27]^[28]

Fezolinetant carries a boxed warning for rare but serious liver injury and requires liver testing before treatment, monthly for the first three months, and again at months 6 and 9. A prescription being nonhormonal does not make it consequence-free.^[29]

One interaction that deserves an actual medication review

Tamoxifen is converted to active metabolites partly through CYP2D6. Current paroxetine labeling tells prescribers to consider an alternative antidepressant with little or no CYP2D6 inhibition because paroxetine can lower active tamoxifen-metabolite concentrations. Do not switch an antidepressant from a web page; have oncology, the prescriber, or a pharmacist review the full list.^[30]

Vaginal estrogen remains a separate conversation. Go to Is vaginal estrogen a different decision?.

Where to go next: our nonhormonal options guide and an oncology or high-risk menopause service.

No provider signup in this section. You need an oncology conversation, not a generic telehealth prescription.

What if my BRCA result was a VUS? {#vus}

A variant of uncertain significance is not the same as a pathogenic or likely pathogenic BRCA variant. It means the laboratory found a change but does not have enough evidence to classify it as harmful. BRCA-specific surgery or HRT rules should not be applied to a VUS as though it were a confirmed mutation.

This trips up a lot of women because the report contains the words “BRCA1” or “BRCA2” and “variant.” Your brain reads BRCA mutation.

It may not be one.

NCI says most BRCA VUS results that are later reclassified are reclassified as benign, and a VUS typically should not drive medical management while its meaning remains uncertain.^[31]

What to do:

Ask a genetic counselor whether the laboratory has reclassified it.
Ask who is responsible for notifying you if classification changes.
Base current risk management on personal history, family history, and other established factors.
Do not undergo BRCA-specific surgery or reject treatment solely because the letters BRCA appear beside a VUS.

Patch, pill, or gel: does route matter for BRCA carriers? {#route}

Route matters mainly because of clotting, stroke, liver, gallbladder, convenience, and symptom considerations rather than because a patch changes the BRCA gene. Transdermal estradiol is generally favored when venous-thromboembolism or stroke risk matters. The route does not erase a breast-cancer contraindication or turn combined therapy into estrogen-only therapy.^[1]

Transdermal estradiol: patches, gels, and sprays avoid first-pass liver metabolism and are associated with lower venous-thromboembolism and stroke risk than oral estrogen in guideline reviews.
Oral estrogen: effective for symptoms, but may be less attractive when clotting or metabolic risk is present.
Vaginal estrogen: local treatment; not a substitute for systemic therapy when hot flashes are the problem.
A uterus still needs protection: changing from pill to patch does not remove the progestogen question.

Compounded and FDA-approved are not the same category

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before marketing, although lawful compounding can serve a real medical need when an FDA-approved product cannot meet a patient’s needs.^[32]

That means:

an FDA-approved estradiol patch and a compounded estradiol preparation must not be presented as equivalent products;
“bioidentical” does not tell you whether a product is FDA-approved;
a custom dose or excipient need can be a legitimate reason to compound;
convenience, marketing language, or “more natural” is not evidence that compounding is safer.

The BGCS/BMS guideline recommends against compounded bioidentical HRT. For a BRCA decision, where the argument depends on what specific products and regimens were studied, an FDA-approved option is the cleaner evidence-aligned starting point when it can meet the patient’s needs.

On dose: women who lose ovarian function early may need a different dose strategy from women starting after natural menopause. That is a prescriber question, not a number for a website to hand out.

What about testosterone after ovary removal? {#testosterone}

Testosterone can be considered for postmenopausal women with distressing hypoactive sexual desire disorder after a full biopsychosocial assessment and after other contributors are addressed. No testosterone product is FDA-approved specifically for women in the United States. Any use is off-label, prescription-only, monitored, and subject to Schedule III controlled-substance rules.

Low desire was a major concern in the FORCE survey, but “low libido” is not one single diagnosis.

The Global Consensus Position Statement says:

the only evidence-based indication is hypoactive sexual desire disorder in postmenopausal women;
no blood-test cutoff diagnoses HSDD;
evidence does not support testosterone for brain fog, fatigue, general wellbeing, mood, or disease prevention;
compounded testosterone is not recommended when a suitable authorized product and dose strategy can be used;
pellets and injections that create supraphysiologic concentrations are not recommended; and
monitoring should keep concentrations within the physiologic female range.^[33]

In the United States, FDA-approved testosterone products are approved only for men with specified medical causes of low testosterone. Use in women is therefore off-label, and testosterone is a Schedule III controlled substance under federal law.^[34]^[35]

The practical distinction most women are never given: if sex hurts, the primary problem may be genitourinary syndrome of menopause rather than absent desire. Local vaginal treatment, pelvic-floor care, or another pain-focused approach may be more relevant than testosterone.

Who should prescribe HRT for a BRCA carrier? {#who-prescribes}

The clinician needs more than a menopause prescription pad. They need to recognize when genetics, breast screening, gynecology, surgery, or oncology must be involved. The BRCA-specific guideline names high-risk cancer gene variants as a reason for specialist menopause referral, so a general online visit is often a bridge — not the whole care team.

Time for us to tell you something that costs us money.

A general online menopause consult is not the right first stop for most women reading this page.

If the unresolved question is whether systemic HRT is appropriate after risk-reducing surgery, which regimen fits your uterus, how it affects breast surveillance, or whether prior cancer changes the answer, that is a multi-team decision. A fast intake form is not built to replace it.

But “specialist first” does not always mean “wait untreated for a year.” A menopause-trained virtual clinic can sometimes become the bridge if it publishes care for gene carriers, reviews the full history, coordinates testing, and knows when to stop and refer.

Provider-stated versus independently verified, August 6, 2026

The HRT Index Verification Standard reviews commercial options on clinical legitimacy, care quality, medication fit, price transparency, and access. The table below does not score providers and does not turn provider marketing into proof of clinical fit.

Care route	What the source states	What we verified	Best fit	Material limits
High-risk breast/genetics clinic + menopause specialist	Multidisciplinary care around inherited cancer risk	BGCS/BMS explicitly lists high-risk cancer gene variants as a specialist-referral indication	Unsettled HRT decision, prior cancer, complex screening or surgery coordination	Access may be slow or geographically limited
Midi Health	Publishes care for cancer survivors and at-risk women, explicitly including women who carry a gene increasing breast-cancer risk; available in all 50 states; HRT for eligible patients plus nonhormonal options	Page was live; Dr. Mindy Goldman was named as overseeing care for survivors and at-risk women; self-pay visits were $250 initial / $150 follow-up; most PPO plans accepted, coverage varies; no Medicaid/Medi-Cal treatment; Medicare beneficiaries may self-pay but cannot submit claims^[14]^[15]	Best-documented virtual bridge we found for a cancer-free carrier who also has an established high-risk team	Does not replace surgery, imaging, genetics, or oncology. Midi publishes FDA-approved HRT options and separate compounded Custom Rx products; confirm the exact prescription and request FDA-approved therapy when that is your requirement. Midi’s current booking guidance says to cancel or rebook at least 24 hours ahead to avoid a cancellation fee; verify the fee in the portal before booking^[16]
Sesame	Marketplace connecting patients with independent clinicians; prescriptions are at clinician discretion	Sesame is not the medical provider; visits are cash-pay; no guarantee of a prescription; Medicare, Medicaid, and TRICARE beneficiaries are not eligible under current terms; controlled substances are not prescribed through Sesame prescription services	Finding a specific cash-pay gynecologist or clinician when you want to choose the individual	No published BRCA program. Expertise, testing, coordination, and price vary by listing. Current terms provide a full refund when a virtual visit is canceled at least 3 hours ahead or an in-person visit at least 24 hours ahead; no-shows and refund requests based on not receiving a prescription are excluded^[17]
General refill/subscription clinic	Usually designed for straightforward menopause intake and ongoing refills	No BRCA-specific pathway is enough reason by itself to recommend one here	Only after the specialist plan is already settled and the clinic agrees to follow it	Wrong first stop for unresolved genetic-risk, cancer, or combined-therapy decisions

The damaging admission: Midi also offers compounded products in parts of its business. If your priority is an exclusively FDA-approved formulary, confirm the exact prescription before paying. The reason Midi still appears here is narrower: among virtual clinics we checked, it publishes the clearest pathway for women who carry a breast-cancer-risk gene and it states that it can coordinate in-person testing.

That is an editorial fit conclusion based on current provider-stated facts — not proof that Midi is right for a particular reader.

Do not choose from a provider table while your medical branch is still unresolved. Find My HRT Path will first flag whether online care belongs in the route, then show a best-fit option and two backups. Check my care route before I book →

What should you verify before paying any HRT provider? {#verification-checklist}

Nine questions reveal quickly whether a clinician handles BRCA carriers routinely or is about to search the topic during your appointment. Ask them before money changes hands. The right answer is not a confident slogan; it is a concrete process for anatomy, cancer history, screening, bone health, medication type, and follow-up.

Ask this	Why it matters	A useful answer sounds like
“Have you treated cancer-free BRCA1 or BRCA2 carriers after risk-reducing ovary removal?”	Separates routine experience from generic menopause care	They can describe the care pathway without confusing carriers with survivors
“How does my uterus change the regimen?”	Tests whether they understand endometrial protection	They ask about hysterectomy, endometrial tissue, and bleeding history before answering
“How do you handle the five-year combined-therapy question?”	Tests whether they know the 2026 subgroup signal	They acknowledge the estimate, its imprecision, and the need for planned reassessment
“Will you coordinate with genetics, breast screening, gynecology, surgery, or oncology?”	This is often a multi-team decision	They explain who communicates with whom and what records they need
“Do you prescribe FDA-approved products, compounded products, or both?”	Prevents category blur	They name the exact product and explain why compounding would be medically necessary
“What monitoring do you recommend after early surgical menopause?”	Bone loss and follow-up are measurable	They discuss DEXA/FRAX, symptoms, bleeding, blood pressure, and relevant in-person care
“What happens around age 51?”	Tests whether duration is being planned rather than ignored	They describe reassessment, not an automatic stop or indefinite autopilot
“What will I pay if insurance denies the visit?”	Avoids surprise billing	A written self-pay price and coverage-check process
“How do I cancel or change follow-up?”	Commercial friction still matters	A written policy before purchase, not a verbal promise

Bring:

your operative report;
the pathology report if surgery has already happened;
your genetic test report with the exact classification;
your current medication list, including tamoxifen, aromatase inhibitors, and any IUD;
your most recent breast-screening plan;
your DEXA result, if one exists; and
the name of the clinician who owns your high-risk surveillance.

“Partial hysterectomy” is not precise enough. The operative report tells you whether ovaries, tubes, cervix, uterus, or endometrial tissue remain.

Where is the evidence still genuinely unsettled? {#unsettled}

Eight gaps remain large enough to change counseling, from the lack of a randomized BRCA trial and thin BRCA2 estimates to limited evidence beyond natural menopause and a concerning but imprecise long-duration combined-therapy subgroup. Product detail, prior cancer, ovaries-intact menopause, and delayed-oophorectomy strategies remain unresolved too.

No randomized trial. Every breast-risk estimate on this page is observational.
BRCA2 precision. The newest studies include BRCA2, but many older studies were BRCA1-only or underpowered by gene.
Duration beyond natural menopause. The specific guideline recommendation is Grade D because the evidence is sparse.
Combined therapy over time. Overall estimates are not clearly elevated, but the under-45, five-year-plus adjusted HR of 2.31 cannot be called neutral.
Product and schedule detail. Studies often group different estrogens, progestogens, routes, schedules, and doses together.
Prior breast cancer. The reassuring 2025–2026 studies excluded survivors.
Natural menopause with ovaries intact. JNCI helps, but the post-RRSO literature cannot simply be copied onto this group.
Risk-reducing salpingectomy with delayed oophorectomy. This two-step strategy is still considered investigational outside research settings in the guideline.

ClinicalTrials.gov study NCT06972719 is developing and testing an educational aid about HRT after risk-reducing ovary removal. It is not an HRT safety trial and will not answer whether a particular regimen causes breast cancer.^[36]

Why there are no testimonials on this page

A patient can truthfully describe whether a clinician listened, whether symptoms improved, or whether a service was easy to use. A testimonial cannot establish cancer safety.

So we did not use a review to prove the medical conclusion. The proof on this page is the study population, the confidence interval, the label section, the guideline grade, and the line where the evidence stops.

Reassurance does not land on this reader.

Evidence does.

Frequently asked questions

Can you take HRT if you have a BRCA mutation?

Often, yes. For a cancer-free woman with a confirmed BRCA1 or BRCA2 pathogenic variant who enters menopause after risk-reducing removal of both ovaries, the most specific guideline says HRT should be offered until around the natural menopause age unless another contraindication applies. Prior breast cancer changes the answer.

Is HRT safe after risk-reducing oophorectomy?

The evidence is reassuring but observational. The overall post-oophorectomy studies have not shown a substantial breast-cancer increase, and estrogen-only findings are the most favorable. There has never been a randomized trial, and prolonged combined therapy is less settled.

Does HRT increase breast-cancer risk in BRCA1 carriers?

Most studies have not found an increase. In the April 2026 JAMA cohort, each year of estrogen-only use was associated with a 13% lower observed risk in BRCA1 carriers. That association does not prove estrogen prevents cancer.

What about BRCA2 carriers?

The broad recommendation after early risk-reducing ovary removal is similar, but there is less gene-specific evidence. Most BRCA2-associated tumors are hormone-receptor-positive, and the JAMA estrogen-only subgroup estimate for BRCA2 was not statistically significant.

Does HRT cancel the benefit of ovary removal?

Short-term HRT did not negate the observed breast-risk reduction in the PROSE cohort, and later studies have not shown a substantial overall increase. That does not settle every regimen or duration.

Do I need progesterone if I kept my uterus?

Systemic estrogen generally needs a progestogen or another accepted method of endometrial protection when a uterus or endometrial tissue remains. A patch instead of a pill does not remove that requirement.

Is estrogen-only safer than combined HRT for BRCA carriers?

The observational evidence is more favorable for estrogen-only therapy. Combined therapy has not shown a clear overall increase, but a 2026 subgroup of women who started after surgery before 45 and used combined therapy for at least five years had an elevated, imprecise estimate.

Should I have a hysterectomy so I can take estrogen alone?

Not solely for that reason. The 2024 BRCA-specific guideline does not recommend hysterectomy at risk-reducing ovary surgery unless another genetic or clinical indication exists.

Is a BRCA mutation an FDA contraindication?

Not in the two current product labels we checked. Divigel and Bijuva list current or prior breast cancer, but neither lists BRCA1, BRCA2, genetic predisposition, or family history in Section 4.

Did FDA remove the boxed warning in 2026?

FDA approved revised boxed-warning language for six menopause hormone products on February 12, 2026. Current or prior breast cancer remains a contraindication in the product labels we checked, and the action did not make all HRT products identical or risk-free.

Can I use HRT if my ovaries are still in place?

Possibly, but the post-oophorectomy evidence is not a direct answer. The newer JNCI cohort included natural and surgical menopause, so it offers supporting evidence; your decision still needs to combine ordinary menopause timing, uterus status, symptoms, and your inherited breast-risk plan.

How long should I stay on HRT after ovary removal?

BRCA-specific guidance supports treatment to roughly the natural menopause age, around 51, then reassessment. Continuation beyond that is not routinely recommended for BRCA carriers because direct evidence is limited, although preventive bilateral mastectomy changes the framework.

Does a preventive bilateral mastectomy change the answer?

Yes. The 2024 guideline says HRT beyond natural menopause can then be considered under ordinary population-risk principles. Residual breast tissue and non-breast HRT risks still exist.

Can I use vaginal estrogen if I cannot use systemic HRT?

Often, yes. Low-dose vaginal estrogen is a local-treatment question and is generally not contraindicated even when systemic HRT is unsuitable. A breast-cancer survivor should still make that decision with oncology after nonhormonal options are considered.

What if I have had breast cancer or DCIS?

Systemic HRT is usually contraindicated and should not be started through a generic online pathway. Severe symptoms may justify an oncology-led, individualized discussion, especially after triple-negative disease, but the reassuring previvor studies do not answer recurrence risk.

What if I take tamoxifen or an aromatase inhibitor?

The HRT decision belongs with oncology. Local vaginal therapy, nonhormonal vasomotor treatment, and antidepressant interactions all need to be coordinated with the cancer regimen.

What if my genetic result is a VUS?

A VUS is not a confirmed pathogenic BRCA variant. It generally should not drive BRCA-specific surgery or treatment decisions while uncertain. Ask a genetic counselor whether it has been reclassified.

Is transdermal estrogen better than oral estrogen?

Transdermal estradiol is often favored when clotting or stroke risk is relevant because it avoids first-pass liver metabolism and is associated with a lower thrombotic risk than oral estrogen. It does not remove breast-cancer or endometrial considerations.

Can testosterone help low libido after surgery?

Possibly, when the diagnosis is distressing hypoactive sexual desire disorder after a full assessment. No testosterone product is FDA-approved for women in the U.S.; use is off-label, prescription-only, monitored, and testosterone is a Schedule III controlled substance.

Should I delay risk-reducing surgery to avoid menopause?

Do not change surgery timing from a webpage. Timing is driven by your gene-specific cancer risk, age, fertility plans, family history, and surgical guidance. Build the symptom, bone, and HRT plan before surgery so fear of untreated menopause is not the only reason you postpone a cancer-prevention decision.^[18]

Can an online provider treat a BRCA carrier?

Sometimes. A virtual menopause clinic may be a bridge for a cancer-free carrier when it publishes care for gene carriers, reviews records, uses appropriate products, and coordinates testing. Prior cancer or an unresolved high-risk decision should start with specialist or oncology input.

My surgeon said no hormones. What should I do?

Ask which fact changes the guideline answer in your case: prior breast cancer, pathology, uterus status, clotting history, liver disease, age, regimen, or another contraindication. Bring the guideline position and ask for the reason in writing. If the answer remains a reflex, a high-risk menopause or genetics-informed second opinion is reasonable.

Sources

Provider verification

Midi Health. Care for Cancer Survivors and At-Risk Women. Checked August 6, 2026.
Midi Health. HRT and Custom Rx. Checked August 6, 2026.
Midi Health. Pricing & Insurance. Checked August 6, 2026.
Midi Health. How do I cancel or reschedule a visit?. Checked August 6, 2026.
Sesame. Terms of Service. Checked August 6, 2026.

One last thing

If you take nothing else from this page, take this:

Your gene is not named in the two current FDA contraindication lists we checked. The most specific guideline says HRT should be offered after premenopausal ovary removal unless there is a personal history of breast cancer. And the evidence is reassuring enough to demand a real explanation — not a reflexive “no hormones with your gene.”

That does not make every regimen safe.

It means you now know exactly where the answer changes.

Still not sure which HRT program is right for you? Take our free 90-second matching tool.

Find My HRT Path →

The HRT Index is editorial research and not medical advice. We are not clinicians, and this page has not been medically reviewed by one. FDA-approved and compounded medications are labeled separately throughout, and compounded products are never presented as equivalent to FDA-approved products. Affiliate disclosure · Consumer health data and privacy

¹ Taylor A, Clement K, Hillard T, et al. BGCS/BMS guideline, 2024.

² Regev-Sadeh S, Michaelson-Cohen R, Madorksy-Feldman D, et al. Hormone Therapy After Oophorectomy and Breast Cancer Risk in Women With BRCA Pathogenic Variant. JAMA Network Open. 2026.

³ Kotsopoulos J, Seca M, Gronwald J, et al. Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2. JNCI. 2026.

⁴ FDA, Divigel prescribing information, Reference ID 5744952, revised February 2026.

⁵ FDA, Bijuva prescribing information, Reference ID 5744948, revised February 2026.

⁶ FDA, FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026.

⁷ FDA, Menopausal Hormone Therapies with Updated Prescribing Information.

⁸ Rebbeck TR, Friebel T, Wagner T, et al. PROSE Study Group. J Clin Oncol. 2005.

⁹ Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and breast cancer risk in BRCA1 carriers. JNCI. 2008.

¹⁰ Kotsopoulos J, Huzarski T, Gronwald J, et al. HRT after oophorectomy in BRCA1 carriers. JAMA Oncology. 2018.

¹¹ Marchetti C, et al. Meta-analysis of HRT after RRSO in BRCA1/2 carriers. 2018.

¹² Michaelson-Cohen R, et al. Breast cancer risk and HRT among BRCA carriers after RRSO. European Journal of Cancer. 2021.

¹³ Kim HY, et al. Short-term post-RRSO HRT in BRCA carriers. 2024.

¹⁴ Midi Health, Care for Cancer Survivors and At-Risk Women, checked August 6, 2026.

¹⁵ Midi Health, Pricing & Insurance, checked August 6, 2026.

¹⁶ Midi Health, How do I cancel or reschedule a visit?, checked August 6, 2026.

¹⁷ Sesame, Terms of Service, checked August 6, 2026.

¹⁸ NCI, BRCA1 and BRCA2: Cancer Risks and Management (PDQ).

¹⁹ Jiang H, Robinson DL, Lee PVS, et al. Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy. Osteoporosis International. 2021;32(1):101–112.

²⁰ Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009.

²¹ Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstetrics & Gynecology. 2013.

²² Xu Z, Chung HF, Dobson AJ, et al. Menopause, hysterectomy, menopausal hormone therapy and cause-specific mortality. Human Reproduction. 2022.

²³ Narasimhan R, Moore JF, Herbach E, et al. Menopausal hormone therapy use and counseling patterns among surgically menopausal BRCA mutation carriers. Journal of Clinical Oncology. 2026;44(16suppl):e12736.

²⁴ Hormone replacement therapy among BRCA mutation carriers. Journal of Clinical Oncology. 2017;35(15suppl):1561.

²⁵ Faubion SS, et al. GSM management in women with or at high risk for breast cancer. 2018.

²⁶ Jörg I, et al. Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors. Journal of Cancer Research and Clinical Oncology. 2026.

²⁷ The Menopause Society, 2023 Nonhormone Therapy Position Statement.

²⁸ FDA, Lynkuet Drug Trials Snapshot. Approved October 24, 2025.

²⁹ FDA, Veozah boxed warning and liver-monitoring requirements, updated December 16, 2024.

³⁰ DailyMed, Paroxetine tablets prescribing information, revised February 2025.

³¹ NCI, BRCA Gene Changes: Cancer Risk and Genetic Testing.

³² FDA, Understanding the Risks of Compounded Drugs.

³³ Davis SR, et al. Global Consensus Position Statement on Testosterone Therapy for Women. 2019.

³⁴ FDA, Testosterone Information, updated June 23, 2026.

³⁵ Drug Enforcement Administration, Drug Scheduling, checked August 6, 2026.

³⁶ ClinicalTrials.gov, NCT06972719, checked August 6, 2026.

Keep genetics, oncology, and menopause decisions connected.

A known BRCA pathogenic variant, prior breast cancer or DCIS, tamoxifen or aromatase-inhibitor use, intact ovaries, or an upcoming risk-reducing operation changes the starting point. Bring the source's nine-factor checklist to your genetics, oncology, gynecology, or high-risk menopause team before booking online care. For a cancer-free carrier with an established specialist plan, the source reviews Midi Health and Sesame; use Find My HRT Path only for the broader provider-model question.

Keep reading: